TB Test for Lower Batch Sizes

A second-generation test is designed for the diagnosis of latent tuberculosis (TB) infection and active TB disease.

The T-SPOT.TB 8 will be marketed by Oxford Immunotec Ltd. (Oxford, UK). The test is the result of a 15-month co-development program with Millipore Corp. (Billerica, MA, USA) to develop a proprietary plate for performing the TB 8 test.

The plate allows the test to be conducted in smaller batches when smaller numbers of tests need to be performed simultaneously, since the plate consists of several 8-well strips, which can be used individually. This test complements the higher throughput 96-well version (T-SPOT.TB 96), which is already being marketed in Europe.

"This represents the achievement of a real milestone in the development of our product range, which will have broad utility across the T-SPOT technology platform,” noted Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec. "By offering a more flexible plate, our customers will be able to maximize the efficiency of their TB testing regimen by utilizing the best format of T-SPOT.TB for the clinical population, while delivering significant potential savings.”

"Millipore is proud to participate in co-developing products that respond to the needs of healthcare professionals worldwide,” observed Jonathan DiVencenzo, vice president of R&D and marketing for the Bioscience Division of Millipore.



Related Links:
Oxford Immunotec
Millipore